Press coverage about USANA Health Sciences (NYSE:USNA) has trended somewhat positive on Monday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. USANA Health Sciences earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2614554357492 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Comparing USANA Health Sciences (USNA) & Foamix Pharmaceuticals (FOMX) (americanbankingnews.com)
- USANA Health Sciences (USNA) Lifted to “Sell” at BidaskClub (americanbankingnews.com)
- Head to Head Review: MediWound (MDWD) & USANA Health Sciences (USNA) (americanbankingnews.com)
- USANA Health Sciences (USNA) Upgraded at BidaskClub (americanbankingnews.com)
- USANA Health Sciences, Inc. (USNA) Major Shareholder Global Ltd Gull Sells 40,000 Shares (americanbankingnews.com)
Shares of USNA stock opened at $93.30 on Monday. The stock has a market capitalization of $2,243.77, a PE ratio of 22.98 and a beta of 0.82. USANA Health Sciences has a fifty-two week low of $52.55 and a fifty-two week high of $94.40.
A number of research analysts have recently weighed in on the company. TheStreet lowered USANA Health Sciences from a “b+” rating to a “c+” rating in a report on Tuesday, February 6th. Pivotal Research increased their price objective on USANA Health Sciences from $80.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Sidoti lowered USANA Health Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, January 24th.
In other news, Director Myron W. Wentz sold 38,223 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $71.51, for a total value of $2,733,326.73. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Global Ltd Gull sold 40,000 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $86.23, for a total value of $3,449,200.00. Following the completion of the sale, the insider now owns 11,214,053 shares in the company, valued at approximately $966,987,790.19. The disclosure for this sale can be found here. Insiders sold 729,767 shares of company stock worth $58,024,833 in the last 90 days. Company insiders own 53.20% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.